EGI
PHAS

EAM Global Investors’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

EAM Global Investors’s Portfolio PHAS Stock Details PHAS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-87,891
Closed -$1.15M – 159
2019
Q2 		$1.15M Buy
+87,891
New +$1.08M 0.49% 115

Other funds holding PHAS

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Global Investors's PHAS Position: Q3 2019 in Review

EAM Global Investors sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2019, closing a stake of 87,891 shares — an estimated $1.15M sold.

EAM Global Investors first reported a position in PHAS in Q2 2019 and held it in 1 quarter. The position peaked at $1.15M in Q2 2019. 58 funds tracked by Wall St. Rank hold PHAS as of Q3 2019.

  • EAM Global Investors reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2019 after selling out during the quarter.
  • EAM Global Investors sold 87,891 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2019, an estimated $1.15M.
  • EAM Global Investors first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q2 2019 and held it in 1 quarter.
  • EAM Global Investors's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $1.15M in Q2 2019.
  • 58 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2019.

Based on EAM Global Investors's 13F filing for Q3 2019, filed 13 Nov 2019.